Source: Fox News
Summary
House Select Committee on the Chinese Communist Party Chairman John Moolenaar is investigating Eli Lilly’s clinical trial operations in China, seeking records related to research conducted at Chinese military-affiliated hospitals and facilities in Xinjiang. The committee is concerned about national security, intellectual property, and human rights risks. Eli Lilly has sponsored or collaborated on over 220 clinical studies in China since 2003. The committee is seeking records from Lilly as it expands its investments and research partnerships in China.
Our Reading
Once again, the discussion returns to a familiar question.
Chairman John Moolenaar demands records from Eli Lilly, citing concerns about national security, intellectual property, and human rights. The company has sponsored numerous clinical studies in China, including at hospitals linked to the People’s Liberation Army and in Xinjiang. Moolenaar stresses that there is no evidence of illegal activity, but the committee is seeking assurance that Eli Lilly’s due diligence procedures are adequate. The inquiry marks an escalation in congressional scrutiny of U.S. pharmaceutical companies’ ties to China.
It’s business as usual in the biotechnology competition between the U.S. and China.
Author: Evan Null
